Savicell is a Liquid ImmunoBiopsy™ company that targets early, non-invasive detection of multiple diseases with a patented immunometabolism platform. In addition, it may be used to track/predict treatment effectiveness, including immunotherapy. This field of “immunometabolism” is emerging in pharmaceutical development, given that a normal metabolic state of the immune system is linked to its ability to combat infectious disease and cancer. There are growing publications linking the spectrum of immune system metabolic states as a basis for categorizing human disease. Savicell is at the forefront of developing diagnostics in this new space.

Disease intrusion and cell malformation, including cancer, are first detected by the immune system, which energizes to rid the body of the malignancy. The initial immune response to disease is intricate, deploying different metabolic pathways and subtypes of cells. Savicell Well-Shield™ technology is designed to detect and interpret these differential metabolic responses as an immune system metabolic test for early detection.

The Company’s initial focus is on early diagnosis of cancer, specifically lung cancer, where the company has peer review published¹ the promising results of its initial 200 subject study which yielded 91% sensitivity and 80% specificity. Importantly, results are equally strong in predicting late and early stages.

Projected liquid biopsies market opportunity is $38bn in US and multi-$billion opportunity in first indication (lung)

Savicell is the only immunometabolism diagnostic company with a unique and growing patent estate. Patents granted include US, EU, CN, JP.


This description contains forward-looking statements subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the company to be materially different from those expressed or implied by such forward-looking statements. Risk Factors are discussed in our periodic reports.